Recent News

• 03.06.2025 - HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
• 03.06.2025 - HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
• 02.03.2025 - HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
• 02.03.2025 - HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
• 01.15.2025 - HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025
• 01.15.2025 - HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025
• 12.23.2024 - HCW Biologics Inc. Received NASDAQ Staff Determination Letter
• 12.23.2024 - HCW Biologics Inc. Received NASDAQ Staff Determination Letter

Recent Filings

• 03.06.2025 - EX-99.1 EX-99.1
• 03.06.2025 - 8-K Current report
• 02.26.2025 - CT ORDER Confidential treatment order
• 02.26.2025 - DEFR14A Revised definitive proxy soliciting materials
• 02.21.2025 - DEF 14A Other definitive proxy statements
• 02.21.2025 - 8-K Current report
• 02.11.2025 - PRE 14A Other preliminary proxy statements
• 02.07.2025 - 8-K Current report
• 02.03.2025 - 8-K Current report
• 02.03.2025 - EX-99.1 EX-99.1